Kimmo S. Salminen

Turku, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Translation and validation of the Rome IV Functional Gastrointestinal Disease questionnaire for adults and prevalence of functional gastrointestinal disorders in the general Finnish population.

Translation and validation of the Rome IV Functional Gastrointestinal Disease questionnaire for adults and prevalence of functional gastrointestinal disorders in the general Finnish population.

Journal: Scandinavian journal of gastroenterology

Published: June 01, 2026

Association Between Proton-Pump Inhibitors and Muscle Strength in Older Adults: A Population-Based Analysis.

Association Between Proton-Pump Inhibitors and Muscle Strength in Older Adults: A Population-Based Analysis.

Journal: Journal of digestive diseases

Published: January 27, 2026

Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial.

Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial.

Journal: The lancet. Gastroenterology & hepatology

Published: February 27, 2025

First local results of the Finnish FIT-based colorectal cancer screening program - high yield, low complications.

First local results of the Finnish FIT-based colorectal cancer screening program - high yield, low complications.

Journal: Scandinavian journal of gastroenterology

Published: February 02, 2025

Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease.

Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease.

Journal: Digestive diseases and sciences

Published: November 26, 2024

Real-life experiences of switching from intravenous to subcutaneous vedolizumab maintenance therapy in patients with inflammatory bowel disease.

Real-life experiences of switching from intravenous to subcutaneous vedolizumab maintenance therapy in patients with inflammatory bowel disease.

Journal: European journal of gastroenterology & hepatology

Published: July 08, 2024

Relationship between frailty, nutrition, body composition, quality of life, and gender in institutionalized older people.

Relationship between frailty, nutrition, body composition, quality of life, and gender in institutionalized older people.

Journal: Aging clinical and experimental research

Published: September 24, 2021

Severe ulcerative proctitis, pyoderma gangrenosum, hidradenitis suppurativa and fever in a patient with a rare variant of the PSTPIP1 gene.

Severe ulcerative proctitis, pyoderma gangrenosum, hidradenitis suppurativa and fever in a patient with a rare variant of the PSTPIP1 gene.

Journal: Clinical and experimental dermatology

Published: May 18, 2021

Associations between Nutritional Status, Frailty and Health-Related Quality of Life among Older Long-Term Care Residents in Helsinki.

Associations between Nutritional Status, Frailty and Health-Related Quality of Life among Older Long-Term Care Residents in Helsinki.

Journal: The journal of nutrition, health & aging

Published: March 03, 2020

Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice.

Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice.

Journal: Biologicals : journal of the International Association of Biological Standardization

Published: October 17, 2018

High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).

High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO).

Journal: Scandinavian journal of gastroenterology

Published: December 21, 2017

Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?

Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?

Journal: Journal of Crohn's & colitis

Published: July 24, 2014

Showing 1-12 of 13

Last Updated: 09/26/2026